Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target

Benzinga · 2d ago
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.